newsroom
Prof. Dr. Bernard Canaud: CONVINCE – the breakthrough trial for high-volume HDF?
Created on 03/08/2023 12:00
Watch the interview with Prof. Bernard Canaud
At the 60th ERA Congress in Milan, Prof. Peter Blankestijn revealed remarkable findings from the CONVINCE trial. This groundbreaking study involved 1,360 patients, with a median follow-up of 30 months, proving that high-volume Hemodiafiltration (HV-HDF) offers significant clinical advantages for patient survival in comparison to more commonly used high-flux Hemodialysis.
Prof. Dr. Bernard Canaud is part of the trial's scientific committee and expressed enthusiasm for implementing HV-HDF as a therapeutic option for dialysis patients. The presented findings from the CONVINCE trial have the potential to reshape dialysis treatments and paves the way for future research and clinical advancements for dialysis patients.
CONVINCE STUDY
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754803.
Watch Prof. B. Canaud talk on the CONVINCE trial here at the Nephrology Campus online !